← FDA DRUG APPROVALS

FDA ANDA · ANDA065076

AMPICILLIN AND SULBACTAM

Sponsor: HIKMA

APPLICATION
ANDA065076
TYPE
ANDA
ORIGINAL APPROVAL
2002-03-19
LATEST ACTION
2009-01-21
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

AMPICILLIN AND SULBACTAMPrescription
AMPICILLIN SODIUM EQ 10GM BASE/VIAL, SULBACTAM SODIUM EQ 5GM BASE/VIAL · INJECTABLE · INJECTION

Approval history

2009-01-21Labeling · Supplement 24AP
2006-03-08Labeling · Supplement 21AP
2004-03-26Labeling · Supplement 11AP
2002-03-19OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →